Search Legislation

Council Regulation (EEC) No 2377/90 (repealed)Show full title

Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)

 Help about what version

What Version

More Resources

Revised version PDFs

Close

This is a legislation item that originated from the EU

After exit day there will be three versions of this legislation to consult for different purposes. The legislation.gov.uk version is the version that applies in the UK. The EU Version currently on EUR-lex is the version that currently applies in the EU i.e you may need this if you operate a business in the EU.

The web archive version is the official version of this legislation item as it stood on exit day before being published to legislation.gov.uk and any subsequent UK changes and effects applied. The web archive also captured associated case law and other language formats from EUR-Lex.

Changes to legislation:

There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed). Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

  1. Introductory Text

  2. Article 1.. . . . . . . . . ....

  3. Article 2.. . . . . . . . . ....

  4. Article 3.. . . . . . . . . ....

  5. Article 4.. . . . . . . . . ....

  6. Article 5.. . . . . . . . . ....

  7. Article 6.. . . . . . . . . ....

  8. Article 7.. . . . . . . . . ....

  9. Article 8.. . . . . . . . . ....

  10. Article 9.. . . . . . . . . ....

  11. Article 10.. . . . . . . . . ....

  12. Article 11.. . . . . . . . . ....

  13. Article 12.. . . . . . . . . ....

  14. Article 13.. . . . . . . . . ....

  15. Article 14.. . . . . . . . . ....

  16. Article 15.. . . . . . . . . ....

  17. Article 16.. . . . . . . . . ....

  18. Signature

    1. ANNEX I

      LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES FOR WHICH MAXIMUM RESIDUE LIMITS HAVE BEEN FIXED

      1. 1. Anti-infectious agents

        1. 1.1. Chemotheurapeutics

          1. 1.1.1. Sulfonamides

          2. 1.1.2. Diamino pyrimidine derivatives

        2. 1.2. Antibiotics

          1. 1.2.1. Penicillins

          2. 1.2.2. Cephalosporins

          3. 1.2.3. Quinolones

          4. 1.2.4. Macrolides

          5. 1.2.5. Florfenicol and related compounds

          6. 1.2.6. Tetracyclines

          7. 1.2.7. Naphtalene-ringed ansamycin

          8. 1.2.8. Pleuromutilines

          9. 1.2.9. Lincosamides

          10. 1.2.10. Aminoglycosides

          11. 1.2.11. Other antibiotics

          12. 1.2.12. Polypeptides

          13. 1.2.13. Beta-lactamase inhibitors

          14. 1.2.14. Polymyxins

          15. 1.2.15. Orthosomycins

          16. 1.2.16. Ionophores

      2. 2. Antiparasitic agents

        1. 2.1. Agents acting against endoparasites

          1. 2.1.1. Salicylanilides

          2. 2.1.2. Tatra-hydro-imidazoles (imidazolthiazoles)

          3. 2.1.3. Benzimidazoles and pro-benzimidazoles

          4. 2.1.4. Phenol derivatives including salicylanides

          5. 2.1.5. Benzenesulphonamides

          6. 2.1.6. Piperazine derivatives

          7. 2.1.7. Tetrahydropyrimides

          8. 2.1.8. Others

        2. 2.2. Agents acting against ectoparasites

          1. 2.2.1. Organophosphates

          2. 2.2.2. Formamidines

          3. 2.2.3. Pyrethroids

          4. 2.2.4. Acyl urea derivatives

          5. 2.2.5. Pyrimidines derivatives

          6. 2.2.6. Triazine derivatives

        3. 2.3. Agents acting against endo- and ectoparasites

          1. 2.3.1. Avermectins

        4. 2.4. Agents acting against protozoa

          1. 2.4.1. Triazinetrione derivative

          2. 2.4.2. Quinazolone derivatives

          3. 2.4.3. Carbanilides

          4. 2.4.4. Ionophores

      3. 3. Agents acting on the nervous system

        1. 3.1. Agents acting on the central nervous system

          1. 3.1.1. Butyrophenone tranquillisers

        2. 3.2. Agents acting on the autonomic nervous system

          1. 3.2.1. Anti-adrenergics

          2. 3.2.2. β2 sympathomimetic agents

      4. 4. Anti-inflammatory agents

        1. 4.1. Nonsteroidal anti-inflammatory agents

          1. 4.1.1. Arylpropionic acid derivative

          2. 4.1.2. Fenamate group derivatives

          3. 4.1.3. Enolic acid derivates

          4. 4.1.4. Oxican derivatives

          5. 4.1.5. Pyrazolone derivatives

          6. 4.1.6. Phenyl acetic acid derivatives

          7. 4.1.7. Sulphonated fenyl lactones

      5. 5. Corticoides

        1. 5.1. Glucocorticoides

      6. 6. Agents acting on the reproductive system

        1. 6.1. Progestogens

    2. ANNEX II

      LIST OF SUBSTANCES NOT SUBJECT TO MAXIMUM RESIDUE LIMITS

      1. 1. Inorganic chemicals

      2. 2. Organic compounds

      3. 3. Substances generally recognised as safe

      4. 4. Substances used in homeopathic veterinary medicinal products

      5. 5. Substances used as food additives in foodstuffs for human consumption...

      6. 6. Substances of vegetable origin

      7. 7. Anti-infectious agents

      8. 8. Anti-inflammatory agents

    3. ANNEX III

      LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES USED IN VETERINARY MEDICINAL PRODUCTS FOR WHICH PROVISIONAL MAXIMUM RESIDUE LIMITS HAVE BEEN FIXED

      1. 1. Anti-infectious agents

        1. 1.1. Chemotheurapeutics

          1. 1.1.2. Benzenesulphonamides

        2. 1.2. Antibiotics

          1. 1.2.1. Beta-lactamase inhibitors

          2. 1.2.2. Macrolides

          3. 1.2.4. Cephalosporins

          4. 1.2.5. Aminoglycosides

          5. 1.2.6. Quinolones

          6. 1.2.9. Polymyxins

          7. 1.2.10. Penicillins

          8. 1.2.11. Florfenicol and related compounds

          9. 1.2.12. Polypeptides

          10. 1.2.13. Lincosamides

          11. 1.2.14. Pleuromutilines

      2. 2. Antiparasitic agents

        1. 2.1. Agents acting against endoparasites

          1. 2.1.1. Phenol derivatives including salicylanides

          2. 2.1.2. Benzimidazoles and pro-benzimidazoles

          3. 2.1.3. Tetrahydropyrimides

          4. 2.1.5. Piperazine derivatives

          5. 2.1.6. Salicylanilides

          6. 2.1.8. Others

        2. 2.2. Agents acting against ectoparasites

          1. 2.2.1. Formamidines

          2. 2.2.2. Iminophenyl thiazolidine derivative

          3. 2.2.3. Pyretrin and pyrethroids

          4. 2.2.4. Organophosphates

          5. 2.2.5. Acyl urea derivates

          6. 2.2.6. Pyrimidines derivatives

          7. 2.2.7. Triazine derivatives

        3. 2.3. Agents acting against endo- and ectoparasites

          1. 2.3.1. Avermectins

        4. 2.4. Agents acting against protozoa

          1. 2.4.1. Carbanilides

          2. 2.4.2. Quinazolone derivatives

          3. 2.4.3. Triazinetrione derivatives

          4. 2.4.4. Other anti-protozoal agents

          5. 2.4.5. Ionophores

      3. 3. Agents acting on the nervous system

        1. 3.2. Agents acting on the autonomic nervous system

          1. 3.2.1. β 2 sympathomimetic agents

          2. 3.2.2. Anti-adrenergics

      4. 5. Anti-inflammatory agents

        1. 5.1. Nonsteroidal anti-inflammatory agents

          1. 5.1.1. Arylpropionic acid derivative

          2. 5.1.2. Enolic acid derivates

          3. 5.1.3. Pyrazolone derivatives

          4. 5.1.4. Sulfonated phenyl lactones

      5. 6. Agents acting on the reproductive system

        1. 6.1. Progestogens

      6. 7. Corticoids

        1. 7.1. Glucocorticoids

    4. ANNEX IV

      LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES FOR WHICH NO MAXIMUM LEVELS CAN BE FIXED

      1. . . . . . . . . . ....

    5. ANNEX V

      Information and particulars to be included in an application for the establishment of a maximum residue limit for a pharmacologically active substance used in veterinary medicinal products

      1. Administrative particulars

        1. 1 . . . . . . . . . ....

        2. 2 . . . . . . . . . ....

        3. 3 . . . . . . . . . ....

        4. 4 . . . . . . . . . ....

        5. 5 . . . . . . . . . ....

        6. 6 . . . . . . . . . ....

        7. A. Safety documentation

          1. A.0. . . . . . . . . . ....

          2. A.1. Precise identification of the substance concerned by the application

            1. 1.1 . . . . . . . . . ....

            2. 1.2 . . . . . . . . . ....

            3. 1.3 . . . . . . . . . ....

            4. 1.4 Classification:

            5. 1.5 . . . . . . . . . ....

            6. 1.6 . . . . . . . . . ....

            7. 1.7 . . . . . . . . . ....

            8. 1.8 . . . . . . . . . ....

            9. 1.9 . . . . . . . . . ....

            10. 1.10 . . . . . . . . . ....

            11. 1.11 Description of physical properties:

          3. A.2. Relevant pharmacological studies

            1. 2.1 . . . . . . . . . ....

            2. 2.2 . . . . . . . . . ....

          4. A.3. Toxicological studies

            1. 3.1 . . . . . . . . . ....

            2. 3.2 . . . . . . . . . ....

            3. 3.3 . . . . . . . . . ....

            4. 3.4 Reproductive toxicity, including teratogenicity.

              1. 3.4.1 . . . . . . . . . ....

              2. 3.4.2 . . . . . . . . . ....

            5. 3.5 . . . . . . . . . ....

            6. 3.6 . . . . . . . . . ....

          5. A.4. Studies of other effects

            1. 4.1 . . . . . . . . . ....

            2. 4.2 Microbiological properties of residues.

              1. 4.2.1 . . . . . . . . . ....

              2. 4.2.2 . . . . . . . . . ....

            3. 4.3 . . . . . . . . . ....

        8. B. Residue documentation

          1. B.0 . . . . . . . . . ....

          2. B.1. Precise identification of the substance concerned by the application

          3. B.2. Residue studies

            1. 2.1 Pharmacokinetics

            2. 2.2 . . . . . . . . . ....

            3. 2.3 . . . . . . . . . ....

          4. B3. Routine analytical method for the detection of residues

            1. 3.1 . . . . . . . . . ....

            2. 3.2 Validation of the method.

              1. 3.2.1 . . . . . . . . . ....

              2. 3.2.2 . . . . . . . . . ....

              3. 3.2.3 . . . . . . . . . ....

              4. 3.2.4 . . . . . . . . . ....

              5. 3.2.5 . . . . . . . . . ....

              6. 3.2.6 . . . . . . . . . ....

              7. 3.2.7 . . . . . . . . . ....

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different versions taken from EUR-Lex as well as any subsequent versions created after exit day as a result of changes made by UK legislation.

The dates for the EU versions are taken from the document dates on EUR-LEx and may not always coincide with when the changes came into force for the document.

For any versions created after exit day as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources